Kodiak Sciences Inc. (KOD)
Largest Insider Buys in Sector
KOD Stock Price History Chart
KOD Stock Performance
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate …
Insider Activity of Kodiak Sciences Inc.
Over the last 12 months, insiders at Kodiak Sciences Inc. have bought $0 and sold $12,453 worth of Kodiak Sciences Inc. stock.
On average, over the past 5 years, insiders at Kodiak Sciences Inc. have bought $187.7M and sold $7.31M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 13,155 shares for transaction amount of $104,363 was made by BAKER FELIX () on 2022‑06‑02.
List of Insider Buy and Sell Transactions, Kodiak Sciences Inc.
| 2024-06-17 | Sale | See Remarks | 2,874 0.0053% | $2.75 | $7,904 | -0.37% | ||
| 2024-06-12 | Sale | See Remarks | 1,558 0.0031% | $2.92 | $4,549 | -3.94% | ||
| 2023-06-16 | Sale | See Remarks | 2,749 0.0054% | $9.23 | $25,373 | -64.83% | ||
| 2023-06-16 | Sale | See Remarks | 2,258 0.0044% | $9.23 | $20,841 | -64.83% | ||
| 2023-06-14 | Sale | See Remarks | 1,448 0.0029% | $9.42 | $13,640 | -64.89% | ||
| 2023-06-14 | Sale | See Remarks | 1,132 0.0023% | $9.42 | $10,663 | -64.89% | ||
| 2022-06-15 | Sale | See Remarks | 2,798 0.0053% | $7.02 | $19,642 | +3.65% | ||
| 2022-06-15 | Sale | See Remarks | 2,282 0.0043% | $7.02 | $16,020 | +3.65% | ||
| 2022-06-02 | 13,155 0.0255% | $7.93 | $104,363 | -6.75% | ||||
| 2022-05-25 | 116 0.0002% | $6.75 | $784 | +10.48% | ||||
| 2022-05-16 | 8,118 0.0163% | $5.99 | $48,599 | +29.47% | ||||
| 2022-02-25 | Sale | Chairman and CEO | 340,000 0.6641% | $8.99 | $3.06M | -12.81% | ||
| 2022-02-24 | Sale | Chairman and CEO | 1M 1.9233% | $9.20 | $9.2M | -16.03% | ||
| 2022-02-17 | 300,000 0.5801% | $54.56 | $16.37M | -85.71% | ||||
| 2022-02-16 | 95,165 0.1782% | $54.12 | $5.15M | -86.03% | ||||
| 2022-02-15 | 5,800 0.0107% | $54.16 | $314,099 | -86.22% | ||||
| 2022-01-31 | 30,148 0.0563% | $57.22 | $1.73M | -86.58% | ||||
| 2022-01-28 | 55,258 0.0977% | $50.42 | $2.79M | -85.58% | ||||
| 2022-01-27 | 262,259 0.5015% | $51.76 | $13.57M | -84.81% | ||||
| 2022-01-25 | 5,500 0.0104% | $58.90 | $323,934 | -86.82% |
Insider Historical Profitability
| BAKER FELIX | 15617369 29.6774% | $5.94 | 3 | 0 | +11.07% | |
| BAKER BROS. ADVISORS LP | 14734965 28.0006% | $5.94 | 41 | 0 | +62.31% | |
| PROFUSEK ROBERT | director | 10000 0.019% | $5.94 | 1 | 0 | <0.0001% |
| Levy Richard S | director | 1000 0.0019% | $5.94 | 1 | 0 | +40.96% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $91.05M | 32.95 | 17.31M | 0% | +$0 | 0.65 | |
| BlackRock | $20.3M | 7.35 | 3.86M | -4.32% | -$916,297.24 | <0.0001 | |
| Acadian Asset Management | $9.06M | 3.28 | 1.72M | -9.72% | -$974,901.07 | 0.03 | |
| The Vanguard Group | $8.7M | 3.15 | 1.65M | +0.67% | +$57,744.28 | <0.0001 | |
| Ecor1 Capital Llc | $8.49M | 3.07 | 1.61M | New | +$8.49M | 0.06 |